Novartis Puts Combination, Cellular Therapies In Spotlight As It Revamps R&D Portfolio
This article was originally published in The Pink Sheet
Executive Summary
Novartis says it has entered a transformational period of growth as its oncologic products continue to advance and its focus expands to include dedicated R&D units for dermatology, heart failure, respiratory and cell therapy.
You may also be interested in...
Novartis Trims Its Sails, Divests Blood-Testing Unit To Spain’s Grifols
CEO Joe Jimenez delivers on his strategy to free up resources at Novartis by divesting its non-core blood transfusion diagnostics business for $1.7 billion.
Novartis’ CDK Inhibitor May Benefit From Swing Back To Single-Arm Trials
As FDA looks toward more flexible cancer drug development standards, advisory panel indicates Novartis’ proposed pediatric indications for CDK inhibitor could be candidate for single-arm studies.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.